The CDC is recommending that people at risk of developing blood clots receive the Moderna or Pfizer/BioNTech vaccines instead of Johnson & Johnson (J&J); the FDA lifts restrictions on mail order access to abortion pills; US health care spending more than doubled during the first year of the pandemic.
As reported by NPR, the CDC accepted recommendations by a panel of experts yesterday who said that the COVID-19 vaccines manufactured by Moderna and Pfizer/BioNTech should be preferred over the Johnson & Johnson (J&J) shot due to growing concerns of rare blood clots. Cases of rare and potentially fatal thrombosis with thrombocytopenia syndrome (TTS), as well as cerebral venous sinus thrombosis, have been indicated to be prevalent in about 1 in every 100,000 cases among at-risk women aged 30 to 49 years. Approximately 15% of TTS cases have been fatal.
As the Supreme Court hears challenges to laws that would limit access to abortions, the FDA announced yesterday it will permanently lift nationwide restrictions on access to abortion pills, which will allow patients to receive the medication by mail instead of having to go in person to a certified health provider. Reported by The New York Times, the move will also allow providers to prescribe abortion pills and send via mail to patients through telemedicine appointments, an action that is banned in 19 states. The FDA said that pharmacies could begin dispensing the abortion pill mifepristone if they become certified by the drug’s manufacturer and if they receive the prescription from a certified health provider.
According to a report published this week in Health Affairs, data from CMS’ Office of the Actuary shows that US health care spending more than doubled in the first year of the pandemic: from a 4.3% increase in 2019 to 9.7% last year. Reported by Politico, most of the increase was attributed to efforts made to contain the spread of COVID-19, with assistance to health care providers, public health programs, and Medicaid payments rising 36% last year. The increase in health care spending was noted to come while the overall economy contracted by 2.2%, in which the medical system accounted for just less than one-fifth of the entire US economy at the end of 2020.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More